Expiration date: 01/2026

Release form

Rectal foam

Composition

1 applique contains mesalazine 1 g.

Packaging

The cylinder 14 AMS.

Pharmacological action

Salofalk worth us anti-inflammatory action. Inhibits the synthesis of metabolites of arachidonic acid (PG), the activity of neutrophil lipoxygenase, inhibits migration, degranulation and phagocytosis of neutrophils, the secretion of immunoglobulins by lymphocytes, binds and destroys free radicals of oxygen.

Testimony

Ulcerative colitis, Crohn's disease.

Contraindications

Hypersensitivity, blood disease, liver failure, children's age (up to 2 years).

Application of pregnancy and breastfeeding

If allows individual course of the disease, in the last 2-4 weeks of pregnancy the drug should be discontinued. At the time of treatment should stop breast-feeding in the absence of sufficient clinical experience with the drug in this period.

Method of application and doses

Rectal in proctitis, proctosigmoiditis and left-sided ulcerative colitis for the treatment of exacerbations apply the foam (1-2 of an application depending on the extent of the lesion), 1 time per day before sleep (need to clean the intestines). Prevention of relapse of ulcerative colitis that is limited to lesions of the rectum, usually effectively already use suppositories 250 mg 3 times a day.

Side effects

Rarely - pain in the abdomen, diarrhea, flatulence, headaches and dizziness, allergic reactions, in rare cases, interstitial nephritis, syndrome, systemic lupus erythematosus, methemoglobinemia, thrombocytopenia.

Special instructions

Salofalk worth us should only be used under medical supervision. Before starting treatment, during therapy (after 14 days after commencement and then every 4 weeks) and after therapy (every 3 months) should be carried out blood and urine tests. For monitoring renal function is recommended to determine the level of urea and creatinine in the serum, the examination of the urine sediment.

Drug interactions

While the appointment may increase the action of coumarin anticoagulants, increasing the toxicity of methotrexate, decrease the diuretic effect of spironolactone and furosemide, decrease the effectiveness of probenecid and rifampicin. Enhances hypoglycemic effect oral protivodiabeticakih funds derived sulfonylureas.